Unit 4 – Antibodies as Drugs and Drug Carriers

Introduction

  • Antibodies (immunoglobulins)

    • Proteins produced by B cells that recognize and bind specifically to antigens.

    • Laboratory-engineered counterparts, monoclonal antibodies (mAbs), are tailored to bind molecules implicated in a disease process.

  • Therapeutic rationale

    • High antigen specificity ⇒ potent efficacy with lower off-target toxicity vs. small molecules.

    • Applicable to cancers, autoimmune disorders, infectious diseases, and emerging precision-medicine indications.

  • Historical context

    • First generation mAbs were 100\% murine, created by hybridoma technology (Köhler & Milstein).

    • Advancing recombinant DNA and phage/yeast display platforms have enabled chimeric, humanized, and fully human formats, reducing anti-drug antibody (ADA) responses.

Antibodies as Drugs – Core Mechanisms of Action

  • Neutralization

    • Antibody binds pathogen or secreted toxin, physically blocking interaction with host receptors (e.g., tetanus, diphtheria antitoxins).

  • Opsonization

    • Fc region engages Fc\gamma receptors on macrophages/neutrophils → enhanced phagocytosis.

  • Complement activation

    • Fc–C1q binding triggers classical complement cascade → membrane attack complex (MAC) and pathogen lysis.

  • Receptor or ligand blockade

    • Example: trastuzumab blocks HER2 dimerization in HER2^+ breast cancer, halting proliferative signaling.

  • Immune-mediated cytotoxicity

    • Antibody-dependent cellular cytotoxicity (ADCC): Fc engages NK-cell Fc\gammaRIIIa.

    • Complement-dependent cytotoxicity (CDC): downstream of C1q, leads to cell lysis.

Typology of Therapeutic Antibodies

  • Monoclonal antibodies (mAbs)

    • Originate from a single B-cell clone ⇢ single epitope specificity.

    • Clinical domains: oncology, immune-mediated inflammatory diseases (IMIDs), infectious diseases, cardiovascular and neurologic disorders under investigation.

  • Molecular humanization spectrum

    • Murine: 100\% mouse; high immunogenicity (e.g., muromonab-CD3).

    • Chimeric: Human constant (Fc + C_{H}1) & mouse variable regions (e.g., rituximab). Immune response lowered by replacing Fc.

    • Humanized: Only CDR loops (~5\% of the total sequence) remain murine (e.g., trastuzumab).

    • Fully human: Obtained via transgenic mice or in vitro selection (e.g., adalimumab).

    • Clinical significance: progressive decrease in human-anti-mouse antibodies (HAMAs) and infusion reactions along this continuum.

Chimeric Antibodies – Design Notes

  • Combine mouse VH/VL with human CH/CL.

  • Eliminate xenogeneic Fc determinants → reduced HAMAs & hypersensitivity.

  • Platform for rapid re-engineering into ADC or bispecific formats by sharing human Fc backbone.

Bispecific Antibodies (BsAbs)

  • Engineered to bind two distinct antigens/epitopes simultaneously.

  • Prototypic mechanism: T-cell redirection

    • One arm binds tumor-associated antigen (TAA); the other binds CD3 on T cells.

    • Cross-links effector with target ⇒ cytolytic synapse formation, T-cell activation, perforin/granzyme release.

  • Alternative architectures: dual-checkpoint blockade, coagulation factor bridging (e.g., emicizumab mimicking factor VIIIa).

Antibody-Drug Conjugates (ADCs)

  • Modular composition

    1. Targeting antibody (mAb or fragment).

    2. Cytotoxic payload (e.g., auristatins, maytansinoids, calicheamicins).

    3. Linker (cleavable: pH-, protease-, or glutathione-sensitive; non-cleavable).

  • Pharmacologic workflow

    1. Antibody binds surface antigen with high copy number (HER2, CD30, CD33, etc.).

    2. Receptor-mediated endocytosis internalizes ADC.

    3. Endosomal/lysosomal conditions cleave linker → payload released.

    4. Payload induces DNA damage or microtubule disruption (e.g., DM1 rup payload, MMAE, calicheamicin) ⇒ apoptotic cell death.

  • Benefits: high therapeutic index; sparing of normal tissue if antigen restricted to tumor.

Mechanisms of Antibody-Mediated Drug Delivery

  1. Enhanced bioavailability

    • Antibody ± FcRn recycling raises plasma half-life (days vs. minutes for peptides).

    • Fc masking shelters small-molecule/peptide from proteases and rapid renal clearance.

  2. Targeted delivery (passive & active)

    • Antibody guides therapeutic cargo to cell type with antigen expression.

    • Lowers systemic exposure, mitigates dose-limiting toxicities.

  3. Intracellular delivery & endosomal escape

    • Receptor-mediated endocytosis imports cargo.

    • pH-labile linkers or fusogenic peptides destabilize endosomal membrane, liberating drug to cytosol.

    • Raises intracellular concentration of siRNA, ASOs, toxins or CRISPR complexes.

Representative Therapeutic Products

  • Trastuzumab (Herceptin®)

    • Target: HER2/neu receptor

    • Indication: HER2^+ breast cancers; gastric cancers.

  • Rituximab (Rituxan®)

    • Target: CD20 on B cells

    • Indication: Non-Hodgkin lymphoma, rheumatoid arthritis, ANCA vasculitis.

  • Adalimumab (Humira®)

    • Target: \text{TNF-}\alpha

    • Indication: Rheumatoid arthritis, Crohn’s disease, psoriasis, uveitis.

  • Bevacizumab (Avastin®)

    • Target: Vascular endothelial growth factor (VEGF-A)

    • Indication: Colorectal, lung, renal, and other solid tumors.

ADCs on the Market

  • Brentuximab vedotin (Adcetris®)

    • Target: CD30; Payload: MMAE

    • Indication: Hodgkin lymphoma, anaplastic large-cell lymphoma.

  • Trastuzumab emtansine (T-DM1, Kadcyla®)

    • Target: HER2; Payload: DM1

    • Indication: HER2^+ metastatic breast cancer.

  • Gemtuzumab ozogamicin (Mylotarg®)

    • Target: CD33; Payload: Calicheamicin

    • Indication: Acute myeloid leukemia.

Safety Considerations

  • Immunogenicity

    • Development of anti-drug antibodies (ADA) ⇒ loss of efficacy, hypersensitivity.

  • Infusion-related reactions

    • Fever, chills, rash, hypotension; mitigated by pre-medication with corticosteroids/antihistamines.

  • Cytokine Release Syndrome (CRS)

    • Massive cytokine surge (IL-6, IFN-γ) causing fever, hypotension, organ dysfunction; managed with tocilizumab/ICU care.

  • Organ-specific toxicity

    • Cardiotoxicity (trastuzumab), hepatotoxicity (inotuzumab ozogamicin), nephrotoxicity, dermatologic AEs.

Efficacy Evaluation – Clinical Trial Endpoints

  • Objective response rate (ORR): complete + partial responses per RECIST in oncology.

  • Overall survival (OS) & progression-free survival (PFS).

  • Patient-reported outcomes (PROs) & quality-of-life instruments (e.g., EORTC QLQ-C30).

  • Biomarker-driven efficacy

    • Target density, mutation status, Fc\gammaR polymorphisms impact ADCC potency.

  • Combination regimens

    • mAb + chemotherapy (R-CHOP), + immune checkpoint inhibitor, + radiation.

Regulatory Landscape

  • U.S. FDA, EMA, PMDA mandate

    • Demonstration of safety/efficacy via Phase I–III trials.

    • Pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity assays.

    • Chemistry, Manufacturing & Controls (CMC): antibody glycosylation, aggregate content, endotoxin.

    • Post-marketing (Phase IV) surveillance for delayed cardiomyopathy, PML, secondary malignancies.

Ethical & Historical Touchstones

  • Past unethical experiments underscore necessity of informed consent & rigorous oversight when trialing biologics:

    1. Tuskegee Syphilis Study (1932\text{–}1972) – withheld penicillin from African-American men.

    2. Willowbrook Hepatitis Study (1956\text{–}1970s) – intentionally infected children.

    3. Guatemala Syphilis Experiments (1946\text{–}1948) – non-consensual STD infection.

    4. Stanford Prison Experiment (1971) & Milgram (1960s) – psychological harm & coercion.

  • Contemporary trials must follow Declaration of Helsinki, Good Clinical Practice (GCP), and institutional review board (IRB) approval to prevent recurrence of such abuses.

Practical Implications & Future Directions

  • Personalized oncology

    • Companion diagnostics (e.g., IHC HER2+++, FISH, NGS) select patients for antibody therapy.

  • Bispecific & tri-specific formats overcoming antigen escape, solid-tumor immunosuppression.

  • Combination with CAR-T or oncolytic viruses for synergistic cytotoxicity.

  • Site-specific conjugation chemistry (e.g., THIOMAB, enzymatic tagging) yields homogeneous ADC with defined drug-to-antibody ratio (DAR) for improved safety.

  • Expansion into non-oncology: anti-PCSK9 for hypercholesterolemia, anti-CGRP for migraine, anti-IL-5 for eosinophilic asthma.

  • Cost & accessibility

    • High manufacturing cost; biosimilar development and novel expression systems (plant, yeast, cell-free) aim to reduce price.

  • Philosophical note

    • Balancing precision medicine’s promise against issues of equity, resource allocation, and long-term immunologic perturbation remains an ongoing societal discussion.fr